TCEANC2 (transcription elongation factor A N-terminal and central domain containing 2) is a nuclear protein with transcription elongation factor activity that mediates protein binding and functions in RNA polymerase II-dependent transcription elongation. The gene is located in the PARK10 locus on chromosome 1 and has been investigated for associations with neurological and inflammatory diseases. TCEANC2 variants, particularly rs10788972, were identified as strongly associated with neuropathologically confirmed sporadic Parkinson's disease in American populations 1, though this association was not replicated in Chinese Han patients 2 or Hungarian populations 3, suggesting population-specific genetic effects. Beyond PD, prenatal mercury exposure was associated with altered DNA methylation patterns at the TCEANC2 locus in newborn cord blood, potentially reflecting mercury-induced changes in cell composition or epigenetic modifications 4. Recent transcriptomic analyses identified TCEANC2 expression in CD16+ neutrophils as part of combined gene signatures for distinguishing Behçet's disease clinical subtypes 5. The gene was also detected in genome-wide homozygosity scans of South American camelids as part of selection signatures in llamas 6. These findings suggest TCEANC2 participates in both transcriptional regulation and disease susceptibility, though its precise molecular mechanisms remain incompletely characterized.